JP6987123B2 - 化合物、試薬およびその使用 - Google Patents

化合物、試薬およびその使用 Download PDF

Info

Publication number
JP6987123B2
JP6987123B2 JP2019503956A JP2019503956A JP6987123B2 JP 6987123 B2 JP6987123 B2 JP 6987123B2 JP 2019503956 A JP2019503956 A JP 2019503956A JP 2019503956 A JP2019503956 A JP 2019503956A JP 6987123 B2 JP6987123 B2 JP 6987123B2
Authority
JP
Japan
Prior art keywords
compound
subject
level
biological sample
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531261A (ja
JP2019531261A5 (https=
Inventor
キボ チャン
アン エム． エバンス
Original Assignee
メタボルン インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボルン インコーポレーティッド filed Critical メタボルン インコーポレーティッド
Publication of JP2019531261A publication Critical patent/JP2019531261A/ja
Publication of JP2019531261A5 publication Critical patent/JP2019531261A5/ja
Application granted granted Critical
Publication of JP6987123B2 publication Critical patent/JP6987123B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019503956A 2016-07-28 2017-07-27 化合物、試薬およびその使用 Active JP6987123B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662367839P 2016-07-28 2016-07-28
US62/367,839 2016-07-28
PCT/US2017/044151 WO2018022866A1 (en) 2016-07-28 2017-07-27 Diagnostic methods, therapeutic agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2019531261A JP2019531261A (ja) 2019-10-31
JP2019531261A5 JP2019531261A5 (https=) 2020-09-03
JP6987123B2 true JP6987123B2 (ja) 2021-12-22

Family

ID=59579921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503956A Active JP6987123B2 (ja) 2016-07-28 2017-07-27 化合物、試薬およびその使用

Country Status (8)

Country Link
US (1) US10865183B2 (https=)
EP (1) EP3491004B1 (https=)
JP (1) JP6987123B2 (https=)
CN (1) CN109563127B (https=)
AU (1) AU2017301949B2 (https=)
CA (1) CA3032116A1 (https=)
ES (1) ES2891088T3 (https=)
WO (1) WO2018022866A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
US11182920B2 (en) * 2018-04-26 2021-11-23 Jerry NAM Automated determination of muscle mass from images
TWI669506B (zh) * 2018-07-06 2019-08-21 國軍桃園總醫院 計算腎絲球過濾率之方法
US12553902B2 (en) * 2019-12-16 2026-02-17 Hill's Pet Nutrition, Inc. Methods, kits and compositions for diagnosing and treating renal disease
CN114026427B (zh) * 2020-05-19 2023-11-17 深圳市中医院 诊断肾病的标志物以及诊断方法
WO2022125056A1 (en) 2020-12-07 2022-06-16 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite
CN119355249A (zh) * 2024-09-20 2025-01-24 长沙都正生物科技股份有限公司 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184836A1 (en) 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
US10393749B2 (en) * 2013-12-11 2019-08-27 Shiseido Company, Ltd. Marker for early diagnosis of kidney failure

Also Published As

Publication number Publication date
CA3032116A1 (en) 2018-02-01
CN109563127B (zh) 2024-01-05
US20190152907A1 (en) 2019-05-23
US10865183B2 (en) 2020-12-15
CN109563127A (zh) 2019-04-02
EP3491004A1 (en) 2019-06-05
ES2891088T3 (es) 2022-01-26
JP2019531261A (ja) 2019-10-31
AU2017301949B2 (en) 2021-09-23
WO2018022866A1 (en) 2018-02-01
AU2017301949A1 (en) 2019-01-31
EP3491004B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
JP6987123B2 (ja) 化合物、試薬およびその使用
US12055535B2 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
US20210116467A1 (en) Diabetes-related biomarkers and treatment of diabetes-related conditions
JP2022091763A (ja) 肝疾患関連バイオマーカーおよびその使用方法
EP2863227B1 (en) Means and methods for metabolic differentiation of non-alcoholic steatohepatitis from liver disease
CN106680473A (zh) 生物标志物在筛选治疗或缓解代谢综合征的药物中的用途
US20250264481A1 (en) Methods for prediction and early detection of diabetes
US11680042B2 (en) Compounds, reagents, and uses thereof
WO2012007531A2 (en) Methods and compositions for diagnosing medical conditions
MX2011001615A (es) Metodo para el diagnostico de esteatohepatitis no alcoholica basado en un perfil metabolomico.
Wang et al. The role of metabolomics in stroke: biomarkers of diagnosis and therapy
US20160195550A1 (en) Metabolism of sod1 in csf
Clendenen et al. High throughput metabolomics in clinical studies: review and new applications to remote ischemic preconditioning
JP7169594B2 (ja) 糖尿病合併症用マーカー
WO2009109647A1 (en) Method for monitoring a metabolic state by measuring inositol phosphate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211130

R150 Certificate of patent or registration of utility model

Ref document number: 6987123

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250